01/20/2025 | Arizona Neuroscience Research | Uncategorized

What is the Moonstone Study?

The Moonstone (Drug: Obexelimab) Study is a groundbreaking clinical trial that aims to assess the safety and effectiveness of obexelimab, an investigational treatment for relapsing multiple sclerosis (RMS). The study provides participants with an opportunity to access an innovative therapy that may help in managing the symptoms of RMS while contributing to medical research.

Why Participate in the Moonstone Study?

Comprehensive Study Design:
The study is designed with multiple phases, including a 12-week randomized placebo-controlled period, a 12-week open-label period, and a 52-week open-label extension. This structure allows participants to receive either obexelimab or placebo during the initial phase and then ensures that all participants have access to the investigational drug in subsequent phases.

No-Cost Care and Travel Reimbursement:
All study-related treatments, medical care, and travel costs will be covered, providing participants with the chance to receive innovative care at no cost. No insurance is required to join the study.

Expert Medical Supervision:
Participants will receive care from experienced neurologists and research staff who will closely monitor their health throughout the study, ensuring the highest level of safety and support.

Study Details and Structure

• Screening Period: A 28-day screening period to confirm eligibility.
• Part A: A 12-week randomized, placebo-controlled period where participants will receive either obexelimab or placebo through weekly subcutaneous (SC) injections.
• Part B: A 12-week open-label period where all participants will receive weekly SC injections of obexelimab.
• Part C: A 52-week open-label extension for long-term observation and treatment.
• Follow-Up Period: A 12-week follow-up to monitor safety after the study ends.

Throughout the study, participants’ B cell levels will be monitored, with additional follow-ups if needed to ensure they return to baseline levels.

Eligibility Criteria

• Diagnosed with relapsing multiple sclerosis
• Age: 18–65
• Additional criteria apply, so individuals are encouraged to complete a brief screening questionnaire to determine their eligibility.

Advancing Multiple Sclerosis Research

By participating in the Obexelimab Study, you contribute to important research that aims to improve treatment options for individuals with relapsing multiple sclerosis. Your involvement supports the development of a potential new therapy and may provide benefits for future patients living with MS.

Get Started Today

Take the first step toward participating in this relapsing multiple sclerosis clinical trial. Visit Arizona Neuroscience Research for more details and learn how to enroll.

Learn about the Obexelimab Study, a relapsing multiple sclerosis clinical trial in Arizona. Join now and help advance research into innovative MS treatments.